BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Daiichi Sankyo
Julphar
Argus Health
Fish and Richardson
Baxter
Deloitte
McKinsey
Cerilliant
UBS

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,208,471

« Back to Dashboard

Which drugs does patent 7,208,471 protect, and when does it expire?

Patent 7,208,471 protects VIBATIV and is included in one NDA.

This patent has eighty-eight patent family members in thirty-four countries.
Summary for Patent: 7,208,471
Title:Glycopeptide phosphonate derivatives
Abstract:Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
Inventor(s): Leadbetter; Michael R. (San Leandro, CA)
Assignee: Theravance, Inc. (South San Francisco, CA)
Application Number:11/265,570
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,208,471

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-001 Sep 11, 2009 DISCN Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-002 Sep 11, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,208,471

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,831,150 Reductive alkylation process ➤ Subscribe
6,906,031 Polyacid glycopeptide derivatives ➤ Subscribe
7,351,691 Glycopeptide phosphonate derivatives ➤ Subscribe
6,620,781 Glycopeptide carboxy-saccharide derivatives ➤ Subscribe
8,101,575 Glycopeptide phosphonate derivatives ➤ Subscribe
7,544,364 Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin ➤ Subscribe
6,872,804 Glycopeptide disulfide and thioester derivatives ➤ Subscribe
7,074,760 Polyacid glycopeptide derivatives ➤ Subscribe
7,067,483 Pharmaceutical compositions containing a gycopeptide antibiotic and a cyclodextrin ➤ Subscribe
7,008,923 Glycopeptide phosphonate derivatives ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,208,471

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 035333 ➤ Subscribe
Austria 337334 ➤ Subscribe
Austria 388960 ➤ Subscribe
Austria 402951 ➤ Subscribe
Austria 416791 ➤ Subscribe
Australia 2001261107 ➤ Subscribe
Australia 5746401 ➤ Subscribe
Australia 5929801 ➤ Subscribe
Australia 5930201 ➤ Subscribe
Australia 5930301 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Accenture
Fuji
Fish and Richardson
Chubb
Farmers Insurance
Federal Trade Commission
Chinese Patent Office
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot